Introduction
Retatrutide and Tirzepatide are two of the most widely studied peptides in current metabolic research. Both are being investigated for their effects on weight regulation and glucose metabolism, but they work through different receptor pathways and have distinct research profiles. This guide breaks down the key differences for researchers comparing the two compounds.
These compounds are sold strictly for laboratory and research use. They are not intended for human consumption, and nothing in this post constitutes medical advice.
What Is Tirzepatide?
Tirzepatide is a dual agonist, meaning it targets two receptor pathways: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Research has focused on how this dual-action mechanism affects insulin secretion, appetite signaling, and energy metabolism in animal and in vitro models.
What Is Retatrutide?
Retatrutide goes a step further as a triple agonist — targeting GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor activity is what distinguishes it in current literature, with researchers investigating whether the third pathway produces more pronounced effects on energy expenditure compared to dual-agonist compounds.
Why Researchers Are Watching Both
The core research question driving interest in both compounds is whether adding more receptor targets produces proportionally better outcomes, or whether it introduces new variables worth studying independently. This is an active area of ongoing research.
Sourcing for Research Use
King’s Compounds supplies both Retatrutide and Tirzepatide as research-grade peptides. Browse our full peptide catalog to compare purity data and available concentrations.